"O Instituto de Pesquisas em Saúde (IPS) integra a Área do Conhecimento de Ciências da Vida da Universidade de Caxias do Sul (UCS), tendo iniciado suas atividades em 2019, a partir da união do Laboratório de Pesquisa em HIV/AIDS (LPHA) e do Instituto de Pesquisas Clínicas para Estudos Multicêntricos (IPCEM), conforme Resolução N° 03/2019 do Conselho Universitário da Universidade de Caxias do Sul."

During the past decade, IPCEM; Instituto de Pesquisa de Estudos Multicêntricos conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 6 clinical trials were completed, i.e. on average, 120% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 6 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "IPCEM; Instituto de Pesquisa de Estudos Multicêntricos" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "IPCEM; Instituto de Pesquisa de Estudos Multicêntricos" are "Heart Failure" (2 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Metastatic Renal Cell Carcinoma" (1 trials), "Ovarian Cancer" (1 trials) and "Renal Cell Carcinoma" (1 trials). Many other conditions were trialed in "IPCEM; Instituto de Pesquisa de Estudos Multicêntricos" in a lesser frequency.

Most popular intervention types in "IPCEM; Instituto de Pesquisa de Estudos Multicêntricos" are "Drug" (6 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (3 trials), "Empagliflozin" (2 trials), "Paclitaxel" (2 trials), "Placebo" (2 trials) and "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "IPCEM; Instituto de Pesquisa de Estudos Multicêntricos" are 5 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "IPCEM; Instituto de Pesquisa de Estudos Multicêntricos". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in IPCEM; Instituto de Pesquisa de Estudos Multicêntricos, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in IPCEM; Instituto de Pesquisa de Estudos Multicêntricos, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".